All High-Throughput Screening (HTS) articles – Page 7
-
ArticleFixing failed drugs: AI solutions for toxicity in drug discovery – part 2
Why do so many drug candidates fail before reaching patients – and can AI help stop the losses? In Part 2, Layla Hosseini-Gerami of Ignota Labs outlines the scope of the toxicity problem and explains why failures often come too late to fix.
-
ArticleThe future of CNS drug development: signs of real progress
New therapeutic approaches are emerging for CNS disorders – but can they overcome the toughest barriers in drug development? Find out what is driving progress and what still stands in the way.
-
NewsTargeting MAPK and PI3K/mTOR pathways halts ovarian cancer growth
A new preclinical study has combined two experimental drugs that effectively block ovarian tumour growth – a strategy that could lead to new treatments against this genetically complex cancer.
-
NewsSlowing intracellular transport boosts potential for RNA therapies
Researchers at the University of Basel and Roche have discovered that slowing the intracellular transport of RNA-based drugs significantly improves their therapeutic impact.
-
WebinarEarly De-Risking: In Vitro Safety Strategies for Pre-IND Success
Safety data is no longer just a regulatory checkbox - it’s a strategic advantage. Discover how in vitro and computational tools reduce the reliance on animal testing and support smarter, earlier decision-making in drug discovery.
-
ArticleFuture-proofing drug development with GenAI
Using GenAI and expert reasoning, drug developers can now explore an asset’s long-term potential as early as the preclinical stage. This shift is helping to reshape pipeline planning and refine therapeutic strategy.
-
NewsHow one carbon atom is changing drug development
Researchers at the University of Oklahoma have found a way to improve drugs by adding just one carbon atom. This simple change could speed up drug discovery and lower costs.
-
ArticleNext-generation drug design: how generative AI can tackle undruggable targets
Generative AI is broadening the boundaries of what is possible in drug discovery. In this article, Murat Tunaboylu, CEO and Co-founder of Antiverse, reveals how the zeitgeist technology is enabling scientists to tackle previously undruggable targets like GPCRs and ion channels to deliver patient impact faster.
-
NewsHigh-throughput NaV1.9 assay to advance pain therapies
Metrion Biosciences has introduced a breakthrough NaV1.9 screening assay, aimed at overcoming historical challenges in pain research and advancing the development of non-opioid treatments.
-
WhitepaperApp Note: High-Throughput Single-Cell Genome Profiling
See how the new Shasta™ Single Cell System enabled high-throughput single-cell DNA-seq library preparation to detect tumor-driving mutations.
-
ArticleUsing knowledge graphs in drug discovery (Part 1): how they link to large language models
In this first interview of a two-part series, Andreas Kolleger explores the convergence of knowledge graphs and large language models. As the head of GenAI innovation at Neo4j, Andreas brings a unique cross-industry perspective on how these technologies can enhance life sciences workflows.
-
WebinarAI-powered drug discovery: Accelerating the development of life-saving therapies
AI in drug discovery is no longer theoretical. It’s already speeding up target identification, improving predictions, and cutting waste. Learn how to apply it in your own discovery pipeline.
-
News
Identifying a new target for metabolic liver disease treatment
Scientists have identified protein tyrosine phosphatase delta (PTPRD) as a key regulator of liver metabolism, offering a potential new drug target for treating metabolic liver diseases like MASLD and MASH.
-
NewsStem cell study uncovers shared genes for hearing and vision repair
New research, led by USC Stem Cell scientists, has identified key genetic barriers to sensory cell regeneration in the ear and eye, paving the way for future drug therapies to restore hearing and vision.
-
WebinarAdvancing ADC Development: End-to-End Solutions from Design to Characterization
Dr. Francisca Neethling from Eurofins Discovery explores the comprehensive process of ADC development, covering payload linker design, optimization, and the bioanalytical and functional characterization of ADC molecules.
-
ArticleABB’s robotics ecosystem: advancing lab efficiency in drug discovery
In this interview with Jose-Manuel Collados, learn how ABB's strategic partnerships and automation technology are improving lab efficiency, enhancing precision and ultimately speeding up the development of life-saving treatments.
-
WebinarSmarter labs, faster results: The power of automation in drug discovery
Manual processes are slowing down your lab. AI and automation can change that, if you know how to use them. In this free webinar, Dr Raminderpal Singh breaks down the technologies, data strategies and tools transforming early drug discovery, so you can stop guessing and start innovating.
-
WebinarReprogramming immunity: designing smarter checkpoint receptor agonists
Join Dr Daniela Cipolletta from Seismic Therapeutic to discover how FcγRIIb clustering enabled the discovery of S-4321, a low-affinity PD-1 agonist that restores immune balance by engaging multiple inhibitory pathways.
-
NewsAI designs peptides for 'undruggable' diseases
A new AI-powered approach is tackling the challenge of 'undruggable' diseases by designing peptides that can bind to and destroy previously untreatable proteins.
-
WebinarAdvancing obesity drug discovery: Cell-based assays for GLP-1 and the G-Suite
Gain valuable insights into the latest advancements in obesity drug discovery and enhance your research capabilities.